Endoscopic nipple-sparing mastectomy through a single hidden axillary incision

MINI-B - Minimally Invasive Endoscopic Mastectomy Using a Single Axillary Incision in Breast Cancer Patients: a Prospective Cohort Study

Not applicable Interventional Fondazione del Piemonte per l'Oncologia · NCT07507890

This project will test whether endoscopic nipple‑sparing mastectomy performed through one hidden armpit incision is safe and practical for women with early‑stage breast cancer or DCIS who want immediate implant reconstruction.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment10 (estimated)
Ages18 Years and up
SexFemale
SponsorFondazione del Piemonte per l'Oncologia Academic / other
Drugs / interventionsradiation
Locations1 site (Candiolo, Turin)
Trial IDNCT07507890 on ClinicalTrials.gov

What this trial studies

MINI-B is a single‑center, prospective study enrolling 10 consecutive adult women with early‑stage invasive breast cancer or ductal carcinoma in situ who are candidates for nipple‑sparing mastectomy with direct‑to‑implant reconstruction. The procedure uses an endoscopic technique through a single concealed axillary incision, following a standardized approach modeled on the center's robotic nipple‑sparing method. Outcomes include technical and perioperative feasibility measures, completeness of resection by margin status, and postoperative complications monitored for three months. Patient‑reported quality of life will be collected using BREAST‑Q and EORTC questionnaires to capture functional and cosmetic outcomes.

Who should consider this trial

Good fit: Ideal candidates are adult women with early‑stage invasive breast cancer or DCIS, small‑to‑medium breasts with ptosis grade 2 or less, no skin or nipple‑areola involvement, and who are eligible for direct‑to‑implant nipple‑sparing mastectomy.

Not a fit: Patients with skin or nipple‑areola complex involvement, lymph node metastases, prior ipsilateral breast surgery or thoracic radiation, BMI over 30, heavy smoking, uncontrolled diabetes, ASA score ≥3, or pregnancy are unlikely to benefit from this approach.

Why it matters

Potential benefit: If successful, this approach could offer comparable cancer control with smaller hidden scars, potentially faster recovery, and improved cosmetic outcomes.

How similar studies have performed: Related endoscopic and robotic nipple‑sparing techniques have shown promising feasibility and cosmetic results in small series, but the single‑axillary endoscopic approach remains relatively novel with limited published data.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Female participants aged 18 years or older.
* Diagnosis of early-stage invasive breast cancer or ductal carcinoma in situ, including multifocal or multicentric disease.
* Candidate for nipple-sparing mastectomy with immediate direct-to-implant reconstruction.
* Small- to medium-sized breasts with ptosis grade 2 or less.
* Written informed consent provided.

Exclusion Criteria:

* Preoperative evidence of skin involvement, nipple-areola complex involvement, lymph-node metastases, inflammatory breast cancer, Paget's disease, mesenchymal breast tumors, or recurrent breast cancer.
* Previous ipsilateral breast surgery.
* Previous thoracic radiation therapy.
* Heavy smoking (\>20 cigarettes/day), uncontrolled diabetes mellitus, or body mass index \>30.
* ASA score 3 or higher.
* Ongoing pregnancy

Where this trial is running

Candiolo, Turin

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Breast Cancer - Ductal Carcinoma in SituBreast CancerBreastEndoscopic Nipple-SparingMastectomyE-NSM
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.